What is CBN?
Myriah Dooley
CBN (Cannabinol) is a cannabinoid produced by the cannabis plant. Like CBD and THC, it has its own properties and its effects are more pronounced when taken in conjunction with other cannabinoids, rather than on its own as an isolate. Like all cannabis, studies on CBN are limited, however, according to the available peer-reviewed research, the following properties of CBN have evidence to support them:
Sedative
Antimicrobial/Antibiotic
Appetite stimulant
Pain-relieving
Delayed onset in neurological disease (study pertaining to ALS)
Keratin production reducer (study pertaining to Psoriasis)
In contemporary adult and recreational use markets, CBN is mostly marketed as a sedative. In a 1975 study (Karniol et al, cited below) CBN was found to be a notable sedative when paired with THC. In multiple studies, the observable effect and mechanism of CBN on neurological receptors was noted to be increased by the presence of THC, whereas the effect of CBN alone or with CBD was not as profound.
How much should I take?
Proof’s CBN tincture was formulated with the available research in mind; at a 1:1 CBN:THC ratio, the tincture is formulated to maximize efficacy. It is also formulated to be low-dose, at 5mg CBN & 5mg THC in each dose (0.5ml), it is designed to be accessible to new users as well as those with higher tolerances. As always, we recommend starting with a small dose and increasing as desired.
Bibliography:
Russo, Ethan B. “Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects.” British Journal of Pharmacology, vol. 163, no. 7, 2011, pp. 1344–1364., doi:10.1111/j.1476-5381.2011.01238.x.
Karniol, Isac G., et al. “Effects of Δ9-Tetrahydrocannabinol and Cannabinol in Man.” Pharmacology, vol. 13, no. 6, 1975, pp. 502–512., doi:10.1159/000136944.
Farrimond, Jonathan A., et al. “Cannabinol and Cannabidiol Exert Opposing Effects on Rat Feeding Patterns.” Psychopharmacology, vol. 223, no. 1, 2012, pp. 117–129., doi:10.1007/s00213-012-2697-x.
Weydt, Patrick, et al. “Cannabinol Delays Symptom Onset in SOD1 (G93A) Transgenic Mice without Affecting Survival.” Amyotrophic Lateral Sclerosis, vol. 6, no. 3, 2005, pp. 182–184., doi:10.1080/14660820510030149.
Appendino, Giovanni, et al. “Antibacterial Cannabinoids FromCannabis Sativa: A Structure−Activity Study.” Journal of Natural Products, vol. 71, no. 8, 2008, pp. 1427–1430., doi:10.1021/np8002673.
Zygmunt, Peter M., et al. “Δ9-Tetrahydrocannabinol and Cannabinol Activate Capsaicin-Sensitive Sensory Nerves via a CB1 and CB2 Cannabinoid Receptor-Independent Mechanism.” The Journal of Neuroscience, vol. 22, no. 11, 2002, pp. 4720–4727., doi:10.1523/jneurosci.22-11-04720.2002.